What Does Elevated Troponin Mean in COVID-19?

Allan Jaffe

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Heart Failure in Women: 2025 Update

Scripps Health

M. Kittleson

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

Bridging the Access Gap for NCD (Non-Communicable Diseases) Care in …

Insights from the World Congress of Nephrology 2025

R. Kalyesubula

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Cardio-Renal Syndrome Management: What Are the Key Factors That Impa…

Patricia Kao

ADA-KDIGO Consensus Report on Diabetes Management in CKD - More Alik…

KDIGO

C. Rhee

Interview with IgA Nephropathy Patient Alex

Leicester IgA Nephropathy

L. Iga Nephropathy

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

New Horizons for Cardiorenal Protection: Q&A Panel Discussion

UT Health San Antonio School of Medicine

R. DeFronzo, K. R. Tuttle, E. Cersosimo, G. Bakris, C. Solis-Herrera, S. Bansal, A. Prasad

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Benefits of Slowing the Heart with Ivabradine

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

Cancer Before Solid Organ Transplant

Fred Hutchinson Cancer Center

C. Blosser

Choosing the Optimal Blood Pressure Medication for My Hypertensive P…

Rivka Ayalon